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ABSTRACT OF THESIS 
 
 
 
 
 
GASTROINTESTINAL BLEEDING EVENTS AND STATIN USE:  
A LARGE PROPENSITY SCORE-MATCHED  
RETROSPECTIVE COHORT STUDY 
 
Literature is conflicting regarding the association between statin use and 
gastrointestinal (GI) bleeding. This study sought to determine whether there is an 
association between statin use and GI bleeding by comparing incidence of 
gastrointestinal events between statin users and an active comparator group.  
 
Data was obtained from a large administrative claims database composed of subjects 
enrolled in a selection of insurance plans throughout the United States from 2009-2014. 
New statin users (exposed) and thyroid medication users (active comparator, unexposed) 
were followed from the baseline period (one year prior to medication initiation) until first 
event, discontinuation, or disenrollment. Subjects were matched using a propensity score 
based on demographics, comorbidities, healthcare utilization, and medication use. Odds 
of gastrointestinal events, including GIH, gastroduodenal (GD) ulcer, and 
gastritis/duodenitis were compared between groups. 
 
The final analysis included 1,442,954 statin users matched using a 1:1 algorithm with 
replacement to thyroid medication users. Frequency of GIH in the unexposed group was 
0.56±0.01% and frequency in the low, moderate, and high-intensity statin users group 
was 0.81±0.03%, 0.91±0.02%, and 0.90±0.05% respectively (p<0.002). Statin users had 
1.81 times the rate of GIH compared to the active comparator group (HR 1.81; 95% 
confidence interval (CI) 1.76-1.86). Hazard ratios for GD ulcer and gastritis/duodenitis 
events were 1.13 (CI 0.618-2.05) and 1.19 (CI 0.796-1.80) respectively. 
 
Practitioners should consider these trends when prescribing statins in patients at high-
risk of bleeding. Additional research is needed to verify the association between statins 
and GIH.  
 
 
 
KEYWORDS: gastrointestinal hemorrhage, statins, HMG-coA reductase inhibitors, 
propensity score matching, time-to-event analysis 
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SECTION ONE: INTRODUCTION 
Statin Use 
3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) 
are widely utilized, with 28% of Americans having used a statin in the last 30 days. 
Among Americans with cardiovascular disease utilization is even higher, approximating 
70% (based on data from 2012).1 Both atorvastatin and simvastatin were in the top ten 
medicines by prescription, equating to nearly 154 million prescriptions per month in 
2014.2 
As with most commonly utilized medications, statins are generally considered safe 
and effective, with the most common adverse effects including mild diarrhea, limb and 
musculoskeletal pain, and elevated serum transaminases (2-20% incidence). Serious 
adverse effects such as rhabdomyolysis and liver damage have been reported to occur at 
<2% frequency.3 In addition to these rare adverse effects, bleeding events such as 
epistaxis and hematuria have also been reported in post-marketing surveillance.  
 Statins are primarily used to treat hypercholesterolemia, due to their inhibition of 
HMG-coA reductase causing decreased cholesterol synthesis in the liver. Outside of 
lipid-lowering effects, statins also result in endothelial protection, plaque stabilization, 
and antithrombotic and antiplatelet effects in the cardiovascular system through reduced 
mevalonate production, which results in decreased activation of small GTP-ases Ras and 
Rho (see Figure 1.1). Due to these cardiovascular protective effects, statins are also 
indicated for both primary and secondary prevention of atherosclerotic cardiovascular 
disease (ASCVD). Patients with ASCVD are often on other antiplatelet or anticoagulant 
medications due to common comorbidities such as myocardial infarction, stroke, and 
thromboses.  
If statins exert a cardiovascular protective effect through the cholesterol synthesis 
pathway, then it is unlikely they would have additional bleeding adverse effects. 
However, there is evidence that suggests statins have anticoagulant and antiplatelet 
activity independent of their lipid-lowering effects. This may result in an increased risk of 
bleeding events, which is especially concerning given that a relatively high proportion of 
statin users are also on anticoagulants. 
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Figure 1.1-Statin Mechanism of Action 
 
 
Proposed Mechanistic Explanations 
 Research into the effect of statins on both the coagulation and the platelet cascades 
suggests that statins may potentially have effects on blood clotting, and thus on bleeding 
events, outside of the cholesterol lowering pathway. Evidence suggests statins decrease 
tissue factor (TF) expression, modify various coagulation factors, and decrease the 
number and activation of platelets. 
Tissue factor is a transmembrane receptor expressed on many cells that surround 
blood vessels.4 Its binding with Factor VIIa is necessary to initiate the extrinsic pathway 
of the coagulation cascade (see Figure 1.2). Colli and colleagues found that lipophilic 
statins (fluvastatin and simvastatin) dose-dependently decreased TF expression by 
preventing an inducer from binding to the TF promoter. This effect was reversed by 
adding mevalonate, which suggests that the TF expression inhibition may be related to 
statins’ effect on the cholesterol synthesis pathway.5 Similar results were found in 
another study, wherein investigators demonstrated that cerivastatin also reduced TF 
expression.6 Ferro et al. was able to verify that this statin-induced reduced TF expression 
does in fact decrease the rate of thrombin generation, and thus the rate of clot formation.7 
The inability to adequately form clots may result in a higher likelihood of bleeding. 
In addition to their effect on tissue factor expression, there is also evidence to suggest 
statins affect other components of the coagulation cascade. Simvastatin has been shown 
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to decrease the rate of prothrombin (factor II) activation, factor Va generation, factor XIII 
activation, and fibrin formation from fibrinogen, as well as increase the rate of factor Va 
inactivation.8 These changes result in the depression of thrombus formation, but there is 
also evidence that statins can increase the rate of thrombus degradation. Dangas et al. 
investigated the effect of statins on the thrombolytic pathway and found that pravastatin 
decreased the amount of plasminogen activator inhibitor-1 and the rate of thrombus 
formation regardless of changes in cholesterol level.9 
The platelet cascade has also been implicated as a mechanism for statin-induced anti-
thrombotic activity. Lovastatin has been shown to dose-dependently reduce platelet 
aggregation (mediated through both collagen and thrombin) and to dose-dependently 
induce platelet apoptosis.10 Another study demonstrated that rosuvastatin impacted the 
platelet cascade in a dose-dependent manner by inhibiting platelet recruitment.11 Further 
evidence of statins’ effect on platelets involves a von Willebrand factor (vWF) cleaving 
protease, ADAMTS13, which is implicated as the main cause of thrombotic 
thrombocytopenia (TTP). Shen et al. found that simvastatin upregulated ADAMTS13 
expression, leading to increased cleavage of vWF, and thus decreased platelet 
activation.12 
 
Figure 1.2-Coagulation and Platelet Cascades 
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Existing Clinical Correlations 
While there are numerous hypotheses for a possible mechanism for statin-induced 
bleeding events, studies investigating the clinical correlation of statin use and bleeding 
have not yielded consistent results. These studies have largely investigated either GI 
bleeds or intracerebral hemorrhages (ICH), as case studies have suggested possible risks 
in these areas. To date, some studies have found a decreased risk of bleeding associated 
with statin use, others suggest an increased risk of bleeding, while other researchers were 
unable to find any association at all (see Table 1.1). 
 
Decreased Risk 
Of the studies that found statin use was associated with a lower risk of bleeding, 
one nested case-control study of warfarin patients with atrial fibrillation found that 
statin use of one year or more was associated with a lower risk of GI bleeding. 
However, investigators did not find a similar association with recent statin use or 
statin use of any duration.13 In a subgroup analysis of the OPUS-TIMI 16 trial, 
investigators found that statin users had lower rates of in-hospital GI bleeding than 
non-users.14 Another study in rats found that simvastatin decreased both gastric 
acidity and the size of indomethacin-induced ulcers.15 A retrospective analysis 
investigating the predictors of ICH found that statins were actually associated with a 
decreased ICH volume.16  
 
Increased Risk 
In contrast, there have also been studies that have reported an increased risk of 
bleeding associated with statin use. There have been reported cases of gastric 
ulceration,17 thrombocytopenia (TCP),10,18–22 thrombotic thrombocytopenic purpura 
(TTP),23–25 and hemorrhagic cystitis26 associated with recent initiation and continued 
use of statins, which have resolved after discontinuation. Varying levels of TCP 
(mild, moderate, and severe) possibly associated with statin use have been reported in 
the literature. When it happens, severe events are more commonly reported. Of the 
twelve case reports associating statins with bleeding, two reported TTP within 24 
hours of beginning a new simvastatin therapy, which improved rapidly after drug 
discontinuation.24,25 Five reports (two of TCP purpura, two of TCP, and one of 
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hemorrhagic cystitis) claimed that the adverse reaction took place within one week of 
statin initiation and again resolved quickly after discontinuation.18–20,23,26 In one case, 
severe TCP occurred after switching from one atorvastatin manufacturer to a new 
generic manufacturer and hadn’t occurred with previous simvastatin therapy. Again, 
this suggests that different statins may have different bleeding risks. Three reports 
posit a causal relationship between statin use, TCP, and gastric ulceration that 
occurred after a few months on statin therapy, but that resolved quickly upon 
switching to simvastatin (from atorvastatin) or discontinuing satin therapy.17,21,27 
Finally, one report claimed that a woman experienced TCP purpura after 3 years on a 
steady dose of simvastatin without any known drug interactions, which improved 
after 2 weeks of stopping the drug.22 While the report makes a convincing argument 
that there are no other possible causes, the fact that the patient had been on therapy 
for so long makes it seem less likely that this report demonstrates a causal 
relationship. There are also incidental findings from randomized controlled trials that 
suggest statin users have higher rates of thrombocytopenia and hemorrhage than non-
users.28,29 Furthermore, two studies in rats showed larger indomethacin-induced 
gastric ulcers in simvastatin, atorvastatin, and rosuvastatin treated rats, which is 
contrary to the previously discussed study in rats.30,31 Outside of GI bleeding and 
ulceration, there have been numerous studies suggesting an increased risk of ICH in 
statin users. These include a secondary analysis of the large SPARCL trial, a meta-
analysis of seven randomized controlled trials, and two retrospective studies.32–35 This 
finding that not all statins equally affect bleeding risk is not unique to this study. 
Some studies have suggested that in addition to a dose-dependent effect, there may 
also be a difference amongst statins based on lipophilicity (suggesting that the 
mechanism is gene-mediated), while others hypothesized a chemical structure 
relationship (finding more synthetic statins have a higher risk). There is also a study 
implicating certain ApoE genotypes as an important factor in the increased risk of 
ICH associated with statin use.36 
 
No Association 
While there have been studies that have found an increased risk of bleeding and 
studies that found a decreased risk of bleeding with statin use, other have investigated 
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the correlation and found no association. For example, one case-control study found 
no association between statin use (current, recent, or past) and upper GI bleeds, while 
another investigated patients treated with a thrombolytic and a statin and also found 
no correlation in the risk for subsequent bleeds.37,38 A meta-analysis of 31 
randomized controlled trials of statin therapy that reported ICH found that active 
statin therapy was not associated with a significant increase in ICH.39 Interestingly, a 
recent retrospective study that initially found a protective effect of statins on major 
bleeds in those treated with anticoagulants later found that this protective effect 
disappeared when users were stratified by age and duration of statin use.40 A second 
retrospective analysis, which was performed with propensity score matching, also 
found no association.41  
 
Overall, investigations into the clinical correlation between statin use and 
gastrointestinal bleeding have given mixed results, and studies are mostly small and/or 
post-hoc.  
 
Table 1.1-Summary of Clinical Correlations 
 Study Type Population Size (n) Outcome Author 
Decreased Bleeding Risk 
 Subgroup analysis Acute coronary syndrome 10 288 Inpatient GI bleeds Atar 
 Case-control A. fib., on warfarin 79 207 Upper GI or ICH Douketis 
 Chart review ICH cases 139 ICH Falcone 
 In vitro Rats 18 Gastric ulcer size Tariq 
Increased Bleeding Risk 
 Subgroup analysis History of stroke or TIA 4 731 Hemorrhagic stroke Huisa 
 RCT Hypercholesterolemic patients 2 195 TCP Miserez 
 RCT Acute myocardial infarction 2 082 TCP, hemorrhage Nikolsky 
 In vitro Rats 48 Gastric ulcer size Özbakis  
 Meta-analysis High-dose statin users 31 099 ICH Pandit  
 Chart review IV thrombolytic users 1 446 ICH Scheitz 
 Case-control Warfarin users 353 489 GI bleeding Schelleman 
 In vitro Rats 150 Gastric ulcer size Timoshin 
 Case-control Hypercholesterolemic patients 558 ICH Woo 
No Bleeding Association 
 Cohort Statin users 6 342 GI hemorrhage Badillo 
 Chart review Alteplase-treated patients 119 ICH Geng  
 Case-control Serious upper GI bleed  3 652 GI bleed Gulmez 
 Meta-analysis Statin users 31 099 ICH  McKinney 
 Cohort A. fib., on anticoagulants 8 188 Minor/major bleed van Rein  
A. fib = atrial fibrillation; GI = gastrointestinal; ICH = intracerebral hemorrhage; RCT = randomized controlled trial; TIA = 
transient ischemic stroke 
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Clinical Relevance 
 Upper GIHs are most often caused by an acidic peptic disease (such as gastric and 
duodenal ulcers, as well as gastritis), followed by variceal bleeding and erosive diseases. 
Diverticulosis and angiodysplasia are the most common causes of lower GIH.42 However, 
if it is the case that statins are in some way associated with an increased risk of GI 
bleeding events, this could have a significant impact on the healthcare system. Studies 
estimate that the incidence of upper GIH is anywhere from 40 to 150 per 100 000 cases 
annually,43 while lower GIH occurs around 20 to 30 per 100 000 cases annually.44 
Furthermore, a 2010 study found that patients who experienced upper GIH had higher 
healthcare utilization and costs in the subsequent 12 months compared to those who did 
not.45 This finding remained significant even after excluding initial hospitalization costs, 
which were on average $11,228 for the upper GIH cohort compared to $3,652 for the 
general population cohort. 
 Furthermore, there is a significant proportion of statin users who are already at a 
higher risk of bleeding due to patients being concurrently treated with antiplatelets and 
anticoagulants. Finding that statins are associated with an increased risk of GI bleeding 
could lead clinicians to weigh the risk to benefit ratio of prescribing this class of 
medication in select groups of patients. The purpose of this study was to investigate 
whether statin use is associated with GI bleeding events by comparing GI bleeding event 
incidence between statin users (exposed) and an active comparator (unexposed) group.   
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SECTION TWO: METHODS 
Study Population 
 This study was a retrospective cohort analysis of subjects enrolled in health plans 
between 2009-2014 gathered from the Truven Health MarketScan® Research Database.46 
The database includes de-identified medical and prescription claims from nearly 350 
private payers. Because this data is de-identified and anonymous, it does not meet the 
federal definition of “human subjects research” and thus is IRB exempt.47  
Subjects aged 30-65 years at the time of first statin or thyroid hormone medication fill 
(index date) as documented by private insurers in the database were analyzed. To ensure 
the analysis included only new users and to avoid data contamination by users of both 
study medications, 12 months of continuous enrollment (allowing a 30-day gap in 
coverage) without a documented fill for either study medication was required (baseline 
period). Follow-up began on the index date and continued until first GI bleeding event 
(GIH, ulcer, gastritis, or duodenitis). Censoring occurred at treatment discontinuation (90 
days after completion of the last study medication), disenrollment, or the end of the data, 
whichever came first. A flow diagram depicting subject selection is visualized in Figure 
2.1-Subject Selection Process Data were retrieved using SAS Enterprise Guide software, 
Version 7.1 of the SAS System for Windows.48 
 
Figure 2.1-Subject Selection Process 
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Exposure and Outcomes 
This study employed an active comparator design. As such, two treatment groups 
were identified using GPI codes: statin users (exposed) and thyroid medication users 
(unexposed) (see Appendix C). Exposed individuals were defined as those with a 
prescription claim for a statin. Subjects were followed until first GI bleeding event 
(whether GIH, ulcer, gastritis, or duodenitis) and were censored at treatment 
discontinuation (defined as 90 days after the last supply of medication was exhausted) or 
disenrollment from the database. 
The primary outcome in this study was GIH, although secondary outcomes of 
gastroduodenal ulcer and gastritis or duodenitis were also documented. GI bleeding 
events were identified from the first three diagnosis codes of both in- and outpatient visits 
documented in the database. These conditions were defined using AHRQ-CCS categories 
153, 139, 140, 70, and 76 respectively. GIH was defined as bleeding in any segment of 
the GI tract from the esophagus to the rectum. GIH diagnosis codes included bleeds of 
any cause. 
Outcome events were defined as an event that occurred between the index fill and 90 
days after the last supply of medication was exhausted.  
 
Confounders 
Subject characteristics during the one year prior to treatment initiation (the baseline 
period) for the included subjects were identified from MarketScan. These variables were 
selected based on literature in the field, factors that might influence the propensity to be 
initiated on statin therapy, as well as factors that might influence the propensity to 
experience a GI bleeding event. In addition to age and sex, several possible confounders 
were included in the analysis.  
Disease burden was determined using both the Charlson Comorbidity Index score and 
its individual components (AIDS, ulcer, congestive heart failure, cardiovascular disease, 
dementia, diabetes with and without complications, liver failure with and without 
complications, any malignancy, myocardial infarction, paralysis, renal failure, and 
rheumatologic diseases).49 Health system utilization was measured using a categorization 
of in- and outpatient visits. Inpatient visits were categorized as 0, 1, or ≥ 2, while 
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outpatient visits were categorized as 0-1, 2-4, 5-6, or > 6. Prescription medication use 
during baseline was also measured by having one or more claims for the following 
medications, which were also used in a similar study41: angiotensin converting enzyme 
inhibitors, antiplatelets, antipsychotics, antithrombotics, aspirin, angiotensin receptor 
blockers, beta-blockers, bisphosphonates, calcium channel blockers, corticosteroids, 
diuretics, diuretics, oral hypoglycemics, proton pump inhibitors, sedatives, selective 
serotonin reuptake inhibitors, testosterone, and warfarin. Definitions for each comorbidity 
and prescription can be found in Appendix B and Appendix C. 
 
Propensity Score Matching 
In this study, a theory-driven approach was used to select which measured baseline 
covariates to include in the final propensity score model.50–54 Of 38 measured baseline 
characteristics, 5 were associated only with exposure and thus were not included, and 12 
were not found to be associated with either exposure or outcome and were also excluded 
(see Table 2.1). Liver disease and diabetes severities were combined into one measure 
each, as were malignancies and metastases.  
Thus, the final propensity score was estimated using a logistic regression that 
included 18 baseline covariates: sex, age category, inpatient visits, outpatient visits, CCI 
score category, AIDS, any ulcer, congestive heart failure, cerebrovascular disease, 
diabetes, liver disease, cancer, renal failure, and use of bisphosphonates, blood thinners, 
corticosteroids, NSAIDs, or PPIs. 
Balance in the matched cohort was assessed using standardized differences (or 
standardized mean difference, SMD). SMD is used to statistically test whether there is a 
difference between the two groups. This study defined imbalance between two groups as 
the absolute value of the standardized difference > 0.1, as is common in the literature.55  
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Table 2.1-Baseline Covariate Association with Exposure and Outcome 
Associated only with 
exposure 
Associated only with 
outcome 
Associated both with 
exposure and outcome 
Associated with neither 
exposure nor outcome 
Myocardial infarction Any ulcers Age56 Dementia56,57 
PVD58 Liver disease59 Sex60 Paralysis 
Use of hypoglycemic Malignancy61 Inpatient visits Pulmonary disease 
Use of non-statin LLA Metastases Outpatient visits Rheumatic disease58 
Use of antipsychotics62 Use of blood thinners CCI score Use of ACEi or ARBs63 
 Use of corticosteroids AIDS Use of beta-blockers 
 Use of NSAIDs43,56,58 CHF64,65 Use of CCBs 
 Use of PPIs Cerebrovascular disease66,67 Use of diuretics 
  Diabetes56 Use of sedatives 
  Renal failure68–71 Use of SSRIs 
  Use of bisphosphonates72 Use of TCAs 
   Use of testosterone 
ACEi = angiotensin converting enzyme inhibitor; ARB = angiotensin receptor blocker; CCB = calcium channel blocker; CHF = 
congestive heart failure; LLA = lipid lowering agents; NSAID = non-steroidal anti-inflammatory drug; PPI = proton pump 
inhibitor; PVD = peripheral vascular disease 
 
In this study, matching was completed with the user-created Stata command                                     
-psmatch2-73 using 1:1 nearest-neighbor matching with replacement with a caliper of 0.25 
the standard deviation of the propensity score. Replacement was used as is recommended 
in the literature when the unexposed group is significantly smaller than the exposed 
group.74 
 
Event Analysis 
 Subjects were followed until first GI bleeding event and were censored at treatment 
discontinuation (defined as 90 days after the last supply of medication was exhausted) or 
disenrollment. The incidence rate per person-time at risk of GIH, ulcer, and 
gastritis/duodenitis was calculated using Poisson regression and was compared between 
exposed and unexposed groups, as well as within the exposed group at different doses. 
The number needed to harm was calculated both using incidence rate and cumulative 
incidence, and a comparison of both values was included in the analysis. 
In addition, a Cox proportional hazard model was used to regress exposure status on 
outcome occurrence and determine hazard ratios for risk over time. Frequency weights 
and a robust variance estimator were used to account for the unexposed subjects used in 
multiple matched pairs, which violate the independent observation assumption in Cox 
regressions.   
 14 
SECTION THREE: RESULTS 
Propensity Score Model 
The output of the logistic regression for propensity score estimation is found in Table 
3.1. As can be seen in Figure 3.1, the propensity scores tend to be higher in the exposed 
group than the active comparator group. Figure 3.2 demonstrates that the distribution of 
propensity scores between the exposed and active comparator groups is identical after 
matching. 
 
Table 3.1-Propensity Score Model 
No. obs = 1 929 762 
c-statistic = 0.7302 
 Odds Ratio 95 % Confidence Interval 
Sex, female 0.261 0.258 0.263 
Age 30-39 yr   
40-49 yr 2.18 2.16 2.21 
50-59 yr 3.30 3.27 3.34 
≥ 60 yr 3.36 3.32 3.40 
No Inpatient Visits   
1 1.12 1.11 1.13 
> 1 1.17 1.15 1.18 
0-1 Outpatient Visits   
2-4 Visits 0.849 0.841 0.856 
5-6 Visits 0.711 0.700 0.721 
> 6 Visits 0.611 0.602 0.619 
CCI Score 0   
1 1.30 1.29 1.32 
2 1.23 1.20 1.25 
3 1.17 1.14 1.21 
4 0.995 0.951 1.04 
5 0.809 0.762 0.859 
≥ 6 0.506 0.484 0.530 
AIDS 3.30 2.98 3.64 
Ulcers 0.814 0.773 0.858 
Congestive heart failure 1.15 1.11 1.19 
Cerebrovascular disease 2.10 2.05 2.15 
Diabetes 1.90 1.88 1.93 
Liver disease 0.452 0.427 0.478 
Cancer 0.522 0.510 0.534 
Renal disease 1.11 1.07 1.15 
Bisphosphonates 1.23 1.20 1.26 
Blood thinners 0.925 0.906 0.944 
Corticosteroids 0.931 0.922 0.939 
NSAIDs 1.15 1.14 1.16 
PPIs 1.13 1.12 1.15 
constant 2.42 2.39 2.45 
AIDS = autoimmune deficiency syndrome; CCI = Charlson Comorbidity Index; NSAIDs = 
non-steroidal anti-inflammatory drugs; PPIs = proton pump inhibitors 
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Figure 3.1-Unmatched Cohort Propensity Score Distribution 
 
 
 
Figure 3.2-Matched Cohort Propensity Score Distribution 
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In this study, 21,552 active comparator subjects were matched to 1,442,954 exposed 
subjects because matching was done with replacement (see Table 3.2). As can be seen in 
Table 3.3, the matched cohort designed without replacement had significantly more bias 
than the one completed with replacement. 
 
Table 3.2-Matching in Active Comparator Subjects 
No. of  
Unexposed Subjects 
Times Used to Match     
an Exposed Subject 
Cumulative Percent of 
Active Comparator Subjects 
10 702 1-6 49.66 
6 633 7-25 80.43 
2 057 26-60 89.98 
1 078 61-140 94.98 
865 141-860 98.99 
217 > 860 100.00 
 
Table 3.3-Matching Algorithm Comparison 
 
Active 
Comparator 
Cases Used 
Exposed 
Cases Used 
Mean 
Bias* 
Median 
Bias 
Unmatched  486 808 1 442 954 16.1% 11.0% 
Matched without Replacement  486 808 486 808 6.2% 4.1% 
Matched with Replacement  21 553 1 442 954 0.4% 0.3% 
* Bias is defined as the standardized residual (difference in means divided by pooled standard deviation) 
 
 
Baseline Characteristics 
After all inclusion and exclusion criteria were applied, the full unmatched cohort 
consisted of 486,808 individuals in the active comparator group and 1,442,954 exposed 
individuals. Baseline characteristics for the unmatched cohort can be found in Table 3.4. 
. These groups differ on most confounders included in the propensity score model. 
Active comparator individuals (thyroid hormone users) were more likely to be female and 
younger, have fewer inpatient but more outpatient visits, and have lower CCI scores. 
Significantly more statin users had diabetes and cerebrovascular disease (24.9% vs. 
12.2% and 5.0% vs. 2.0, respectively), whereas significantly more thyroid hormone users 
had liver disease and cancer (0.48% vs. 0.27% and 8.2% vs. 4.1%, respectively). In the 
full unmatched cohort, 0.89% of statin users experienced a GIH, compared to 0.80% in 
the active comparator (standardized difference -0.01).  
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After matching on the propensity score, the exposed and active comparator groups 
were much more similar (see Table 3.5). Of note, statin users used the medication for an 
average of 279±325 days while active comparators used thyroid hormone for an average 
of 326±333 days. Statin users were followed for an average of 252±284 days, and active 
comparators were followed for an average of 331±301 days.   
When comparing those who experienced the primary outcome to those who did not, 
significantly more subjects with the outcome took moderate intensity statins (see 
Appendix C for a definition of statin intensities), had more than six outpatient visits, and 
used blood thinners, corticosteroids, and PPIs. However, significantly fewer subjects who 
experienced the primary outcome had no inpatient visits, had none or one outpatient visit, 
and had a CCI score of 0 than those who did experience the outcome. Exact incidence by 
outcome group can be found in Appendix E. 
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Table 3.4-Unmatched Cohort Baseline Characteristics 
 Active Comparator 
n=486 808 
Exposed 
n=1 442 954 
Standardized 
Difference 
Female, n (%) 387 087 (79.52) 722 564 (50.08) -0.648 
Age Categories, n (%)   0.342 
30-39 y.o.  92 713 (19.05) 108 562 (7.52)  
40-49 y.o. 132 623 (27.24) 345 783 (23.96)  
50-59 y.o. 172 734 (35.48) 642 961 (44.56)  
≥ 60 y.o. 88 738 (18.23) 345 648 (23.95)  
Inpatient Visits, n (%)   0.046 
0 331 991 (68.20) 947 453 (65.66)  
1 101 535 (20.86) 328 123 (22.74)  
> 1 53 282 (10.95) 167 378 (11.60)  
Outpatient Visits, n (%)   -0.160 
0-1 268 932 (55.24) 896 393 (62.12)  
2-4 130 495 (26.81) 358 511 (24.85)  
5-6 34 248 (7.04) 79 264 (5.49)  
> 6 53 133 (10.91) 108 786 (7.54)  
CCI, n (%)*   0.107 
0 338 171 (69.47) 825 573 (57.21)  
1 82 053 (16.86) 402 794 (27.91)  
2 36 455 (7.49) 114 681 (7.95)  
3 14 806 (3.04) 61 719 (4.28)  
4 4 039 (0.83) 16 369 (1.13)  
5 2 181 (0.45) 8 050 (0.56)  
≥ 6 9 103 (1.87) 13 768 (0.95)  
Comorbidities, n (%)    
AIDS 573 (0.12) 3 998 (0.28) 0.036 
Ulcer 2 296 (0.47) 6 540 (0.45) -0.003 
Congestive heart failure 5 124 (1.05) 25 114 (1.74) 0.059 
Cerebrovascular disease 9 746 (2.00) 71 587 (4.96) 0.162 
Diabetes 59 330 (12.19) 359 363 (24.90) 0.332 
Liver disease 2 353 (0.48) 3 940 (0.27) -0.034 
Cancer 39 740 (8.16) 63 962 (4.43) -0.154 
Kidney disease 6 474 (1.33) 25 154 (1.74) 0.034 
Medication Usage, n (%)**    
Bisphosphonates 10 311 (2.12) 28 316 (1.96) -0.011 
Blood thinners*** 13 775 (2.83) 60 506 (4.19) 0.074 
Corticosteroids 93 180 (19.14) 243 557 (16.88) -0.060 
NSAIDs 111 443 (22.89) 345 828 (23.97) 0.025 
PPIs 78 359 (16.10) 255 535 (17.71) 0.043 
* As defined by Deyo et al. ** At least one prescription claim in baseline period, using GPI codes *** 
Includes aspirin, antiplatelets, antithrombotics, and warfarin 
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Table 3.5-Matched Cohort Baseline Characteristics 
 Active Comparator 
n=1 442 954 
Exposed 
n=1 442 954 
Standardized 
Difference 
Female, n (%) 722 274 (50.1) 722 562 (50.1) 0.000 
Age Categories, n (%)    
30-39 y.o.  106 958 (7.4) 108 560 (7.5) 0.004 
40-49 y.o. 342 710 (23.8) 345 783 (23.9) 0.005 
50-59 y.o. 643 926 (44.6) 642 956 (44.6) -0.001 
≥ 60 y.o. 349 341 (24.2) 345 636 (24.0) -0.006 
Inpatient Visits, n (%)    
0 951 277 (65.9) 947 452 (65.7) -0.006 
1 327 073 (22.7) 328 118 (22.7) 0.002 
> 1 164 585 (11.4) 167 365 (11.6) 0.006 
Outpatient Visits, n (%)    
0-1 894 629 (62.0) 896 378 (62.1) 0.002 
2-4 358 528 (24.9) 358 509 (24.9) -0.000 
5-6 79 003 (5.5) 79 264 (5.5) 0.001 
> 6 110 775 (7.7) 108 784 (7.5) -0.005 
CCI, n (%)*    
0 827 883 (57.4) 825 573 (57.2) -0.003 
1 407 762 (28.3) 402 794 (27.9) -0.008 
2 111 549 (7.7) 114 675 (8.0) 0.008 
3 60 339 (4.2) 61 718 (4.3) 0.005 
4 14 922 (1.0) 16 369 (1.1) 0.010 
5 7 432 (0.5) 8 050 (0.6) 0.006 
≥ 6 13 048 (0.9) 13 756 (0.9) 0.005 
Comorbidities, n (%)    
AIDS 3 112 (0.2) 3 988 (0.3) 0.012 
Ulcer 5 429 (0.4) 6 540 (0.5) 0.012 
Congestive heart failure 22 228 (1.5) 25 114 (1.7) 0.016 
Cerebrovascular disease 65 980 (4.6) 71 570 (4.9) 0.018 
Diabetes 363 274 (25.2) 359 346 (24.9) -0.006 
Liver disease 3 611 (0.3) 3 938 (0.3) 0.004 
Cancer 65 291 (4.5) 63 960 (4.4) 0.004 
Kidney disease 23 770 (1.7) 25 154 (1.7) 0.007 
Medication Usage, n (%)**    
Bisphosphonates 28 164 (2.0) 28 314 (2.0) 0.001 
Blood thinners*** 61 032 (4.2) 60 505 (4.2) -0.002 
Corticosteroids 242 186 (16.8) 243 552 (16.9) 0.003 
NSAIDs 345 256 (23.9) 345 816 (23.9) 0.001 
PPIs 258 341 (17.9) 255 529 (17.7) -0.005 
* As defined by Deyo et al. ** At least one prescription claim in baseline period, using GPI codes *** 
Includes aspirin, antiplatelets, antithrombotics, and warfarin 
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Event Analysis 
 Amongst those who experienced the primary outcome (GIH), the average duration of 
medication therapy for users was 505±448 days compared to 629±414 days for the active 
comparator group. Statin users who experienced the primary outcome did so after an 
average of 252±284 days of therapy, in comparison to 331±301 days of therapy for the 
active comparator group.  
The frequency of GIH in low, moderate, and high intensity statin users was 
0.81±0.03%, 0.91±0.02%, and 0.90±0.05% respectively (two sample t-test p<0.002; see 
Figure 3.3). For reference, a chart indicating which statin doses are included in each 
intensity can be found in Appendix C. 
 
Figure 3.3-Outcome Frequency by Statin Intensity 
 
 
 Comparing the rates of GIH between users and the active comparators, statin users 
had 1.81 times the rate of GIH compared to the active comparator group (HR 1.81; 95% 
CI 1.76-1.86; Table 3.6). Hazard ratios for secondary outcomes were not statistically 
significant. Of note, the Cox Proportional Hazards model met all assumptions, but 
because single subjects were used in multiple matched pairs, a robust variance estimator 
was used. Using the incidence rate, the number of patients needed to be treated with a 
statin to cause one GIH (number needed to harm; NNH) was 249. Using the cumulative 
incidence, NNH for the primary outcome was 298. 
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Table 3.6-Outcomes by Study Group 
Outcome 
Active Comparators Statin Users 
Hazard 
Ratio 
95% CI No. of 
subjects 
Rate per 100 
person-yr 
No. of 
subjects 
Rate per 100 
person-yr 
GI Hemorrhage 8 009 0.490 12 866 0.891 1.81 1.05 3.10 
GD Ulcer 2 749 0.167 2 802 0.193 1.13 0.618 2.05 
Gastritis/Duodenitis 17 832 1.10 19 713 1.37 1.19 0.796 1.80 
 
 
A time to event analysis is reflected in the Kaplan-Meier survival curve seen in 
Figure 3.4. Amongst subjects who experienced GIH, 12.25% experienced it within one 
month of therapy initiation, 54.89% within six months, 69.07% within 12 months, and 
97.67% within three years. The maximum time to event amongst those who experienced 
the outcome was four years and nine months. 
 
Figure 3.4-Matched Cohort Kaplan Meier Survival Estimates 
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SECTION FOUR: DISCUSSION 
To our knowledge, this is the largest study that has investigated the association 
between statin use and gastrointestinal bleeding events. The rigorous study design, along 
with the robust analytic methods offer healthcare providers additional evidence to factor 
into their decisions when prescribing statins to patients at a high risk of bleeding. 
Because there have been other retrospective cohort studies that have investigated this 
same question but have come to different conclusions, it is reasonable to discuss the 
rationale behind the study design choices that may have influenced these results. 
 
Study Design 
Any study using retrospective data analysis must include in its design methods to 
combat the inherent biases present. One of these biases occurs when comparing exposed 
to unexposed individuals using users and non-users of the study drug. Non-users are 
fundamentally different than users, predominantly in their health-seeking behaviors, 
though also in other areas such as use of chronic and preventive medications. This study 
utilizes an active comparator design, which is a well-validated method for reducing bias 
in retrospective cohort studies. Schneeweiss and colleagues have shown that increasing 
levels of restriction in observational studies brings study designs closer to that of a 
randomized controlled trial (RCT).75 Based on a review of the literature, most studies 
utilizing active comparator designs use either topical anti-glaucoma medications or 
thyroid hormone substitution.58  
The choice of following subjects for 90 days after treatment discontinuation was 
based on the available evidence associating bleeding with statins. A plausible mechanism 
may include clotting factor XIII inhibition, which has a half-life of 200 hours. Since on 
average, it takes five half-lives for a substance to disappear, complete inhibition of factor 
XIII would result in depletion after 41 days. Thus, it would be reasonable to conclude 
that if a patient has not taken a statin for 41 days that any effect would start to diminish. 
Increasing this interval to 90 days would allow for complete regeneration of factor XIII 
back to baseline. 
 23 
Propensity Score Model 
Another method this study used to reduce bias is propensity score matching (PSM). 
The propensity score balances the distribution of baseline covariates between the exposed 
and unexposed by estimating “the probability of treatment assignment conditional on 
observed baseline characteristics.”76 However, the specification of the propensity score 
model and the choice of algorithm used to match individuals are of utmost importance 
and can significantly change results. For this reason, it is important that both choices are 
thoughtfully made based on available literature.  
Namely, the decision to match either with or without replacement is crucial to result 
interpretation. When matching without replacement is performed, an unexposed case is 
removed from the pool after it is used, which results in later matches having a larger 
difference in propensity score (leading to greater bias in the model). In matching with 
replacement, the closest unexposed individual is matched with an exposed individual, 
allowing the unexposed case to be used multiple times if it is the best match for many 
exposed cases. In the literature, matching with replacement is not commonly used. A 
meta-analysis of propensity score-matched medical studies completed in 2007 
demonstrated that approximately 30% of studies stated that matching without 
replacement was used, but the rest did not state whether matching was done with or 
without replacement.77 Dehejia and Wahba recommend that when the unexposed and 
exposed groups are significantly different, or the unexposed group is small relative to the 
exposed group, that matching with replacement results in better matches.74 Based on 
these guidelines, this data is better suited to matching with replacement. Because the 
same untreated subject can be used in multiple matched pairs, however, it does require 
that the statistics account for this lack of independence in the pairs that have the same 
untreated individual.77 For this reason, robust variance estimators were used to account 
for clustering within matched pairs. Even so, there is a concern about bias if the active 
comparator subjects selected to be matched are outliers and do not represent most 
subjects. In this study, 21,552 active comparator subjects were matched to 1,442,954 
exposed subjects (see Table 3.2). This can be alarming, but is reassuring to note that 
nearly 90% of active comparator subjects were reused ≤ 60 times. Given that the exposed 
group is composed of roughly 1.5 million subjects, this is not a large proportion. The 
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maximum number of times one active comparator subject was reused to match an 
exposed subject was 62,339. 
Because matching with replacement is not commonly reported in the literature and 
there are concerns of bias, the matching algorithm was run again without replacement to 
ensure the best model was employed. It has been shown that matching without 
replacement leads to more bias because the algorithm may be forced to use less optimal 
matched pairs,74 but both models were run for completeness’ sake. As can be seen in 
Table 3.3, the matched cohort designed without replacement had significantly more bias 
than the one completed with replacement. A comparison of both models is discussed in 
Appendix D. Importantly, both models reach the conclusion that there is a significant 
association between statin use and gastrointestinal hemorrhage.  
To determine whether the model accurately represents the data, we can view it both 
graphically and statistically. Graphically, we can compare the distribution of propensity 
scores in the exposed and active comparator groups. Because the propensity score is a 
balancing score, we would want the two groups to be similar. 
As can be seen in Figure 3.1, the propensity scores tend to be higher in the exposed 
group than the active comparator group. This is expected: since these are the subjects 
who were treated with statins, they have a higher probability of being treated. This 
distribution also demonstrates the importance of performing a match with replacement. 
As can be seen, there are significantly fewer active comparator subjects in the upper 
range of the propensity scores. Matching without replacement would mean that once 
these were used to match exposed subjects, later pairs would be worse matches. 
To assess whether the algorithm resulted in “good” matches, it is possible to use a 
variety of statistical measures. In the past, t-tests and p-values have been used, but simply 
comparing means between variables isn’t very useful, since units may be different. Thus, 
there has been a shift in the literature toward using the standardized mean difference 
(SMD), which compares means in a unit-less way independent of sample size. The SMD 
is also much less dependent on sample size, since it uses the standard deviation in its 
calculation. A value of zero means that the two exposure groups have equivalent effects. 
The values increase as the differences between exposed and active comparator groups 
increase.78  
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While there is no globally accepted method to interpret standardized difference, many 
studies use an absolute value > 0.1 as the definition of imbalance between two groups.79 
As seen in Table 3.4, the active comparator and exposed groups differ on nearly every 
measured baseline characteristic in the unmatched cohort. However, the matched cohort 
(seen in Table 3.5) has a much more even distribution between the exposure groups (no 
standardized differences > 0.02). These findings suggest that the matching algorithm was 
successful. 
 
Event Analysis 
The unmatched cohort’s baseline characteristics were unsurprising, in that the active 
comparator group was generally healthier and younger than the user group. There was a 
statistically significant difference between the two groups in sex and age, as well as in 
diabetes and cancer incidence. However, the active comparator group was more similar to 
the user group than a non-user group would have been. As an example, in a recent 
propensity score-matched cohort study investigating the same matter, non-users differed 
significantly on age, sex, inpatient and outpatient encounters, as well as in their 
comorbidity scores.41 This difference demonstrates the power of an active comparator 
group in removing unnecessary baseline bias between comparison groups. 
 After cohorts were matched using the propensity score, there were no statistically 
significant differences between groups on baseline characteristics. However, it should be 
noted that the user group duration of medication therapy was on average shorter than in 
the active comparator group. This might be explained by the fact that in general, statin 
users experience more adverse effects than thyroid hormone medication users which may 
have caused earlier therapy termination.  
Subjects who experienced a GIH were different in some ways than those who did not, 
which is significant because initially both statin users and active comparators were well 
matched. Predictably, there were more blood thinner and corticosteroid users in amongst 
subjects who experienced the outcome, but there were also more PPI users. This is 
interesting because in general, PPIs are thought to be protective of many types of GI 
damage. This may be because those who experienced a GIH had first experienced an 
ulcer and were put on a PPI as a result. In fact, 0.96% of subjects who experienced a GIH 
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in the follow-up period previously had a gastroduodenal ulcer, compared to only 0.19% 
of subjects who did not experience a GIH. The fact that these subjects previously had GI 
damage may mean that they were at a higher risk, and may explain why more were taking 
PPI therapy.  
Another interesting difference is that those who experienced the primary outcome 
used medication therapy for an average of approximately 8 months longer than those who 
did not experience the primary outcome, but were also followed for a longer period of 
time. This trend was consistent amongst statin users and active comparators. While this 
information may make the association between treatment and outcome less clear, the time 
to event analysis elucidates more details. The significant hazard ratio and the Kaplan-
Meier survival curve demonstrate that at any particular time, 1.81 times as many subjects 
in the statin user group experience an outcome compared to the active comparator group. 
Over half of the subjects who did experience a GIH did so within six months of therapy 
initiation, suggesting that there is also a time-related effect. When calculating the NNH, 
using the incidence rate (which takes into account person-time) resulted in a lower 
number than using the cumulative incidence (which does not take into account time). 
This indicates that there is a temporal relation to the association between statin use and 
GIH. Although ulcers, gastritis, and duodenitis did not have statistically significant 
hazard ratios, the trend persisted even amongst these secondary outcomes. This time to 
event analysis helps to remove some of the bias that is associated with having differing 
follow-up times for each subject. 
Looking at the difference in the primary outcome incidence amongst statin users, 
there is no statistically significant difference between the moderate- and high-intensity 
statin users, while low-intensity statin users have significantly fewer instances of the 
primary outcome than both moderate- and high-intensity users. These results are in line 
with previous in vitro studies that have found dose-dependent associations between 
statins and bleeding events. This finding may call into question current prescribing 
guidelines that recommend starting statin doses at the highest tolerable dose and adjusting 
based on adverse effects, such as the 2013 ACC/AHA Guideline on the both primary and 
secondary prevention of ASCVD.80 Conversely, the most recently released United States 
Preventive Services Task Force (USPSTF) guidelines recommend initiating a low- or 
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moderate-intensity statin, suggesting that there is not sufficient evidence to determine 
which statin dosing strategies are the most clinically effective.81 Given the ample 
evidence linking higher dose statins to more adverse effects, the addition of the 
information in this study would support starting at a lower statin intensity and titrating up 
to effect. 
 
Strengths and Weaknesses 
 As discussed, previous studies have attempted to demonstrate an association between 
statin use and gastrointestinal bleeding events, but few have produced clinically 
meaningful results. In early 2015, a retrospective propensity-score matched cohort study 
investigated the possible association between upper GIH and statin use, finding neither an 
increased nor decreased risk of GIH in statin users. Although the sample size was limited, 
it was larger than any that had previously been studied to that point (6 342 statin users 
matched 6 342 non-users).41 For this reason, it is reasonable to view the previously 
mentioned study as a benchmark on which to improve, which this study has strived to 
achieve.  
Using propensity score matching to adjust for baseline differences in treatment 
exposure and an active comparator design to reduce health-seeking behavior bias, this 
study attempts to approximate a randomized controlled trial in design. The design of 
propensity score model was done rigorously, and in line with current recommendations in 
the literature. In contrast to other studies that include a wide variety of baseline covariates 
to estimate propensity scores without justification (such as the 2015 Badillo study)41, this 
study includes only true and potential confounders (covariates related only to the 
outcome and those related both to exposure and outcome).  
 In addition, the study population represents a diverse group of individuals with claims 
from nearly 350 payers throughout the United States. Censoring mechanisms were 
chosen carefully to fulfill an analysis while treated instead of an intention to treat design. 
Instead of following subjects until first event or disenrollment, as done in previous 
studies, a censoring point 90 days after treatment discontinuation was chosen carefully 
based on mechanistic hypotheses. Furthermore, a strong biological plausibility for an 
association was established in this study through intensive background research. 
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 While every attempt was made to reduce bias and produce robustly accurate results, 
certain limitations should be discussed. Foremost is the fact that propensity score 
modeling is very much an art, as much as a science. Particularly, the choice of covariates 
follow no rigorous guidelines, but rather are based on available literature in the field. 
Thus, a different estimation of propensity scores may produce drastically different 
results. While every attempt was made to create a model that considered all aspects that 
may impact propensity for statin treatment, there is nevertheless room for variation. 
Particularly, the PSM accounted for baseline use of blood thinners, which we defined as 
receipt of a prescription for an anticoagulant, antiplatelet, antithrombotic, or aspirin in the 
12-months prior to the index date. However, most patients do not use third-party claims 
to pay for aspirin so its use would likely not appear in our model. Because statin users are 
more likely use aspirin than thyroid hormone medication users (due to confounding 
indications), there may be more statin users on blood thinners than accounted for in our 
model. 
 Moreover, this study did not consider the effect of subjects re-initiating therapy at a 
later date or switching therapy within the class. Subjects were considered as having 
discontinued therapy if a gap of more than 90 days occurred in the prescription claim 
database. Finally, it should be noted that the oldest subjects in this study were 65 years of 
age at treatment initiation, with the average age of 52.8 years old. Because more patients 
are being treated with statins for primary and secondary cardiovascular event prevention 
at greater ages, this study may not represent a clinically relevant population. 
 In the future, studies may consider adding more elderly patients into the analysis to 
make results more comparable to clinical prescribing habits. As an extension of this 
study, a time-varying analysis may be undertaken to account for an individual subject 
stopping and re-initiating therapy at a later date. It is clear from this data that many 
subjects had gastrointestinal bleeding events after censoring due to treatment 
discontinuation, and still more at multiple episodes of treatments with gaps interwoven. 
Using a more sophisticated analysis may be able to take into account these higher level 
usage patterns and more closely approximate a realistic hazard ratio.   
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Conclusions 
In comparing the frequency of events amongst statin users, both moderate and high 
intensity statin users had higher a higher frequency of GIH than low intensity statin users. 
However, this trend did not persist in the secondary outcomes, nor was there a 
statistically significant difference in primary or secondary outcome frequency between 
moderate and high intensity statin users. This finding suggests that GI bleeding adverse 
effects may be associated with increased statin dosage, as has been suggested in the 
literature.  
 This study is the largest known retrospective study investigating the association 
between statin therapy and gastrointestinal hemorrhage. In a cohort of 2,885,870 
propensity score-matched individuals aged 30-65 years, this study found that statin 
therapy statistically significantly increased the rate of GIH by 81%. Clinically, this effect 
size is surprising, but it should be noted that the benefits of statin therapy on 
cardiovascular health continue to outweigh the risk of gastrointestinal bleeding events in 
most patients. 
 In the paramount JUPITER study, the effect of statin therapy on the rate of 
cardiovascular events was investigated.82 In this study, 17,802 healthy adults were 
randomized to rosuvastatin 20 mg or a placebo. Investigators found that the rate of major 
cardiovascular events was reduced by 43% in rosuvastatin users compared to the placebo 
group (HR 0.56; 95% CI 0.46-0.69). This is quite significant clinically, and clinicians 
would do well to note that based on the results of the JUPITER study, the number of 
patients needed to treat with a statin to prevent one major cardiovascular event is merely 
25. This is in comparison to the results of this study, which demonstrate that nearly 250 
subjects need to be treated before one experiences a GIH. While these are stark 
differences, it should be noted that JUPITER and this study are not directly comparable. 
While this study considered all instances of GIH, JUPITER considered only “major” 
instances. Presumably, if one were to restrict GIH events to only those that required 
hospitalization the number needed to harm would become even more alarming. 
Furthermore, only healthy patients were included in the JUPITER study, whereas this 
study strove to include patients with a variety of comorbidities to more accurately 
represent a clinically relevant population. When considering whether to prescribe a statin 
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for cardiovascular protection, the risk of GIH is small for the general population and 
statin benefits likely outweigh the risks. 
 In conclusion, this propensity score-matched cohort study demonstrated that a group 
of statin users had significantly higher rates of gastrointestinal hemorrhage than a similar 
group of thyroid hormone users. The results of this study may influence clinical decision 
making in a select group of patients who are at a higher baseline risk of bleeding. In 
patients who take anticoagulants or antiplatelets, or who have bleeding disorders, the risk 
of cardiovascular events should be weighed carefully with the risk of GIH from statins. 
While statins offer significant benefits in reducing cholesterol levels and cardiovascular 
disease, this new insight may guide clinicians in making treatment decisions for patients 
at higher baseline risks of bleeding.   
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APPENDIX A : THYROID HORMONE AND GASTROINTESTINAL BLEEDING 
 
 Because this study employs a design with thyroid hormone users as the active 
comparator, it was necessary to conduct a search of the literature to determine whether 
there was any association between thyroid hormones and GI bleeding that could bias the 
study. If there is some correlation between use of thyroid hormone and likelihood of GIH, 
using these subjects as active comparators in a study investigating GIH may not be the 
best method. 
The thyroid gland is in the neck, just in front of the larynx. Its secreted hormone, T4, 
is the precursor to T3, which modifies gene transcription and thus protein synthesis in 
most tissues. Both T4 and T3 are well-known to affect nearly every organ and system in 
the body.  
The three major targets of thyroid hormone are the bone, the heart, and metabolism 
regulation. Hypothyroidism has been associated with poor bone development in infancy, 
whereas hyperthyroidism is associated with osteoporosis in adults (as T3 stimulates 
osteocalcin).83,84 In the heart, hypothyroidism causes bradycardia as T3 stimulates cardiac 
myocytes. In fact, thyroid hormones impact nearly every part of the cardiovascular 
system including hypertension and various cardiovascular diseases.85 Both T3 and T4 can 
“enhance cardiac function, promoting weight loss and reducing serum cholesterol.”86 
Although this is a potential confounder with our statin users, excluding all statin users 
who use thyroid hormones as well as thyroid hormone medication users who also use 
statins will ideally eliminate this bias. The weight loss component of thyroid hormone is 
due to its regulation of the metabolic rate, including its effects on glucose tolerance.87 
Thyroid hormones also have an important role in hematology. Important effects include 
stimulating red blood cell and hemoglobin production, so hypothyroidism can lead to 
both micro- and macrocytic anemia,88 but other studies suggest that this isn’t a clinically 
meaningful effect. However, a PubMed search for “thyroid AND bleed” provided only 19 
results – none of which demonstrated a correlation between hyper- or hypothyroidism 
and risk of hemorrhage.89  
A PubMed search was also completed for “thyroid*[Title] AND 
thrombocyto*[Title]” since thrombocytopenia is an important risk factor for GIH. Of the 
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38 results, 11 pointed to an association between immune thrombocytopenia (ITP) and 
auto-immune thyroid disease, such as Hashimoto’s disorder. However, this association 
appears to be more related to an auto-immune disorder than the presence of hyper- or 
hypothyroidism because ITP is also associated with other auto-immune disorders 
unrelated to the thyroid gland. 
Overall, while thyroid hormones are impactful on many body systems, it does not 
appear that there is sufficient evidence to suggest any meaningful clinical correlation 
between thyroid hormone substitution and GIH. 
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APPENDIX B : ICD-9 DIAGNOSIS CODES 
 
Comorbidity ICD-9 Code 
Myocardial infarction 410.x, 412.x 
Congestive heart failure 428.x 
Peripheral vascular disease 443.9, 441.x 785.4, V43.4, Procedure 
38.48 
Cerebrovascular disease 430.x-438.x 
Dementia 290.x 
Chronic pulmonary disease 490.x-505.x, 506.4 
Rheumatic disease 710.0, 710.1, 710.4, 714.0-714.2, 714.81, 
725.x 
Peptic ulcer disease 531.x-534.x 
Mild liver disease 571.2, 571.4-571.6 
Diabetes without chronic complication 250.0-250.3, 250.7 
Diabetes with chronic complication 250.4-250.6 
Hemiplegia or paraplegia 344.1, 342.x 
Renal disease 582.x, 583-583.7, 585.x, 586.x, 588.x 
Any malignancy, except malignant 
neoplasm of the skin 
140.x-172.x, 174.x-195.8, 200.x-208.x 
Moderate or severe liver disease 456.0-456.21, 572.2-572.8 
Metastatic solid tumor  196.x-199.1 
AIDS/HIV 042.x-044.x 
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APPENDIX C : MEDICATIONS BY CLASS AND GPI CODES 
 
Medication or Class GPI Code 
Angiotensin-converting enzyme inhibitor 3610x, 369915x, 369918x 
Angiotensin receptor blocker 3615x, 369945x, 369930x, 369940x, 
369965x 
Antiplatelet 8515x 
Antipsychotic 59x 
Antithrombotic 8560x 
Aspirin 6410001x 
Beta-blocker 33x, 369920x 
Bisphosphonate 300420x 
Calcium channel blocker 34x, 369915x, 369945x, 369930x, 
369968x 
Corticosteroid 2210x 
Diuretic 37x, 369920x, 369918x, 369945x, 
369940x, 369968x, 369960x, 369990x 
Hypoglycemic 27997x, 2720x 
Non-statin lipid lowering agent 3910x, 3930x, 3950x, 3999x 
Non-steroidal anti-inflammatory drug 6610x 
Proton pump inhibitor 4927x, 499960x, 499930x 
Sedative 6010x, 6020x 
Selective serotonin reuptake inhibitor 5816x, 629950x 
Statin 279930x, 3940x, 399940x, 409925x 
Testosterone 2310x 
Thyroid hormone 281x, 9664508400, 9664584700, 
9680569110 
Tricyclic antidepressant 5820x, 6040x, 629920x, 629940x 
Warfarin 8320003020 
 
 
Statin Intensity Chart 
High Intensity Statins Moderate Intensity Statins Low Intensity Statins 
atorvastatin 40 – 80 mg atorvastatin 10 – 20 mg simvastatin 10 mg 
rosuvastatin 20 – 40 mg rosuvastatin 5 – 10 mg pravastatin 10 – 20 mg 
 simvastatin 20 – 40 mg lovastatin 20 mg 
 pravastatin 40 – 80 mg fluvastatin 20 – 40 mg 
 lovastatin 40 mg pitavastatin 1 mg 
 fluvastatin 80 mg  
 pitavastatin 2 – 4 mg  
* Adapted from Stone et al., 2013  
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APPENDIX D : PROPENSITY SCORE MODEL AND MATCHING 
The following is the distribution of propensity scores in the complete, unmatched cohort: 
 
 Mean Std. Dev. Minimum Maximum 
Active Comparator 0.648 0.169 0.051 0.983 
Exposed 0.781 0.136 0.044 0.985 
Total 0.748 0.156 0.044 0.985 
 
As shown, the region of common support (0.051 – 0.983) does not include all subjects, so 
the common support restriction must be used.  
 
We initially ran the one-to-one nearest neighbor propensity score matching algorithm 
with replacement and without caliper and find that the maximum difference between 
propensity scores in matched pairs is 0.150. The literature suggests it should be a 
maximum of one-fourth the standard deviation of the propensity score in the unmatched 
cohort.90 Thus, we will institute a caliper of 0.03989. 
 
We run another one-to-one nearest neighbor propensity score matching algorithm with 
replacement on the logit of the propensity score instituting the common support 
requirement and a caliper of 0.03989. We exclude 19 exposed subjects who did not meet 
the common support requirement. The results are as follows: 
 
ATT Exposed Active Comparator S.E. 
Unmatched 0.00892 0.00802 0.000154 
Matched 0.00892 0.00555 0.000993 
 
Because we matched with replacement, 21 552 unexposed subjects were matched to 1 
442 935 exposed subjects. This resulted in 8 009 unexposed subjects (0.56%) with a GIH 
in the follow up period and 12 866 (0.89%) of the exposed subjects. 
 
We also ran a one-to-one nearest neighbor propensity score matching algorithm without 
replacement, instituting the same caliper as the previous model. However, this did not 
result in a good match, as the average difference in propensity scores within a matched 
pair was 0.0256, compared to the previous algorithm which was 0.000005. We instituted 
a caliper of 0.001 with the following results: 
 
ATT Exposed Active Comparator S.E. 
Unmatched 0.00892 0.00802 0.000154 
Matched 0.00883 0.00826 0.000197 
 
Because we matched without replacement and imposed a common support requirement, 
only 436 067 exposed subject were matched to 436 067 unexposed subjects. This resulted 
in 3 601 unexposed subjects (0.83%) with a GIH in the follow up period and 3 852 
(0.88%) of the exposed subjects. 
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APPENDIX E : BASELINE CHARACTERISTICS BY OUTCOME GROUP 
 
 No Outcome 
n=2 864 995 
Outcome  
n = 20 875 
Standardized 
Difference 
Female, n (%) 1 435 196 (50.9) 9 640 (46.2) 0.111 
Age Categories, n (%)    
30-39 y.o.  214 204 (7.5) 1 314 (6.3) 0.066 
40-49 y.o. 684 512 (23.9) 3 981 (19.1) 0.166 
50-59 y.o. 1 277 345 (44.6) 9 537 (45.7) -0.031 
≥ 60 y.o. 688 934 (24.05) 6 043 (28.95) -0.157 
Statin Intensity, n (%)    
Low 283 995 (9.9) 2 309 (11.1) -0.053 
Moderate 1 013 682 (35.4) 9 357 (44.8) -0.274 
High 132 392 (4.6) 1 200 (5.8) -0.072 
Inpatient Visits, n (%)    
0 1 886 689 (65.9) 12 040 (57.7) 0.239 
1 649 261 (22.7) 5 930 (28.4) -0.187 
> 1 329 045 (11.5) 2 905 (13.9) -0.103 
Outpatient Visits, n (%)    
0-1 1 780 836 (62.2) 10 171 (48.7) 0.386 
2-4 711 333 (24.8) 5 704 (27.3) -0.080 
5-6 156 937 (5.5) 1 330 (6.37) -0.054 
> 6 215 889 (7.5) 3 670 (17.6) -0.434 
CCI, n (%)*    
0 1 644 161 (57.4) 9 295 (44.5) 0.367 
1 802 980 (28.0) 7 576 (36.3) -0.251 
2 224 327 (7.8) 1 897 (9.1) -0.064 
3 120 996 (4.20) 1 061 (5.1) -0.058 
4 30 865 (1.1) 426 (2.0) -0.111 
5 15 316 (0.5) 166 (0.8) -0.045 
≥ 6 26 350 (0.9) 454 (2.17) -0.144 
Comorbidities, n (%)    
AIDS 7 051 (0.3) 49 (0.2) 0.003 
Ulcer 11 908 (0.4) 61 (0.3) 0.029 
Congestive heart failure 46 585 (1.6) 757 (3.6) -0.177 
Cerebrovascular disease 136 140 (4.8) 1 410 (6.8) -0.122 
Diabetes 717 161 (25.0) 5 459 (26.2) -0.036 
Liver disease 7 422 (0.3) 127 (0.6) -0.075 
Cancer 128 045 (4.5) 1 206 (5.8) -0.084 
Kidney disease 48 300 (1.7) 624 (3.0) -0.122 
Medication Usage, n (%)**    
Bisphosphonates 55 996 (2.0) 482 (2.3) -0.035 
Blood thinners*** 119 936 (4.2) 1 601 (7.7) -0.209 
Corticosteroids 480 407 (16.8) 5 331 (25.5) -0.305 
NSAIDs 685 810 (23.9) 5 262 (25.2) -0.042 
PPIs 508 893 (17.8) 4 977 (23.8) -0.212 
* As defined by Deyo et al. ** At least one prescription claim in baseline period, using GPI codes *** 
Includes aspirin, antiplatelets, antithrombotics, and warfarin 
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